Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Inst Of Health Nih, Immunex CorpfiledCriticalNat Inst Of Health Nih
Priority claimed from NZ278740Aexternal-prioritypatent/NZ278740A/en
Publication of NZ329403ApublicationCriticalpatent/NZ329403A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
The specification describes a method for treating b-cell lymphomas characterized by neoplastic cells that express CD40. The method involves administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40.
NZ329403A1993-12-231994-12-21Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L
NZ329403A
(en)
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Humanized antibodies, methods for producing thereof, a method for treatment of Crohns disease, a method for treatment OF disseminated sclerosis, pharmaceutical composition